secwatch.observer — SEC 8-K summary
======================================

Issuer:     Medicus Pharma Ltd. (MDCX)
CIK:        0001997296
Form:       8-K
Filed at:   2026-09-03T12:00:27+00:00
Accession:  0001062993-26-004806
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Medicus signs co-development license with Pfizer for CD228V ADC; $1B milestones
-------------------------------------------------------------------------------

- Exclusive worldwide license from Pfizer to develop/commercialize CD228V, an early-stage antibody-drug conjugate targeting CD228.
- Medicus pays $12.0M upfront plus $15.0M on first anniversary; Pfizer pays $2.0M development funding payment.
- Pfizer eligible for development, regulatory, and sales milestones exceeding $1.0B total, plus low double-digit tiered royalties.
- Medicus retains sole control over development, manufacture, regulatory approval, and commercialization; Pfizer holds option to fund pivotal trials.
- Deal effective September 2, 2026; filed as Exhibit 10.1 with redactions for confidential terms.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1997296/000106299326004806/0001062993-26-004806-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1997296/000106299326004806/form8k.htm
  HTML page:      https://secwatch.observer/filing/0001062993-26-004806

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer